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Autoimmune lymphoproliferative syndrome (ALPS) is char-
acterized by autoimmune features and lymphoproliferations and
is generally caused by defective Fas-mediated apoptosis. This
report describes a child with clinical features of ALPS without
detectable Fas expression on freshly isolated blood leukocytes.
Detection of FAS transcripts via real-time quantitative PCR made
a severe transcriptional defect unlikely. Sequencing of the FAS
gene revealed a 20-nucleotide duplication in the last exon affect-
ing the cytoplasmic signaling domain. The patient was homozy-
gous for this mutation, whereas the consanguineous parents and
the siblings were heterozygous. The patient reported here is a
human homologue of the Fas-null mouse, inasmuch as she
carries an autosomal homozygous mutation in the FAS gene and
she shows the severe and accelerated ALPS phenotype. The
heterozygous family members did not have the ALPS phenotype,
indicating that the disease-causing FAS mutation in this family is
autosomal recessive. (Pediatr Res 47: 336–343, 2000)
Abbreviations
ALPS, autoimmune lymphoproliferative syndrome
TCR, T cell receptor
PB, peripheral blood
MNC, mononuclear cells
TCRB, TCRb gene
RT-PCR, reverse transcriptase PCR
RQ-PCR, real-time quantitative PCR
GAPDH, glyceraldehyde-3-phosphate dehydrogenase
CT, cycle number in which the fluorescent signal exceeds the
threshold value
ALPS is characterized by lymphadenopathy, splenomegaly,
accumulation of nonmalignant CD42CD82TCRab1 T cells,
and several autoimmune features, such as autoantibody pro-
duction and autoimmune hemolytic anemia (1). It is caused by
a defect in apoptosis mediated by Fas (also designated CD95,
Apo1, or Apt1). ALPS features are highly comparable to the
phenotype of mice with lpr or gld mutations, which carry an
autosomal recessive mutations in the FAS gene or in the gene
encoding Fas ligand (FASL), respectively, causing autoimmu-
nity, lymphoproliferations and accumulation of
CD42CD82TCRab1 T cells (2–4). There are three mouse
strains carrying different FAS mutations i.e. the lpr, the lprcg
and the Fas-null strains (2, 5). Although these mice have a
similar phenotype, there are differences in severity and the time
of development of the symptoms (6).
Both FasL and Fas are transmembrane proteins, which
belong to the tumor necrosis factor and tumor necrosis factor
receptor family, respectively (7, 8). Fas is expressed as a trimer
on peripheral activated lymphocytes and also in tissues such as
liver, lung, heart, and ovary. The intracellular part of the Fas
protein contains a death domain, which is essential for the
induction of apoptosis on interaction of Fas and FasL trimers
(9). Fas-mediated apoptosis is needed for the elimination of
autoreactive T lymphocytes that escaped thymic selection, but
seems not to be involved in negative selection of immature
cells in the thymus (10–12). The Fas-FasL interaction also
appears to be important in B cell homeostasis and is involved
in the control of immune responses (13, 14). A soluble form of
Fas without the transmembrane domain (FasDTM) has been
shown to be capable of inhibiting Fas-mediated apoptosis by
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blocking membrane bound FasL in vitro (15). The human FAS
gene consists of 9 exons and is located on chromosome 10
(16–18).
The patients with ALPS that have been described thus far
show largely comparable clinical features, with variation in
severity (1, 19–24). We herein present a new patient in whom
Fas protein expression studies were followed by extensive
molecular analysis of the FAS gene of the patient as well as her
parents and siblings. The unique genotype and phenotype of
this patient are discussed in the context of previously described
patients with ALPS and the different mouse strains with dis-
tinct FAS gene mutations.
METHODS
Clinical report. The patient is a girl from consanguineous
parents. She has three healthy siblings, but two other siblings
died at the ages of 1.5 and 2 y. Immediately after the girl’s
birth, petechiae, generalized edema, and hepatosplenomegaly
were noticed. During the first month of life, autoantibodies
against red blood cells and platelets were demonstrated. A liver
biopsy showed extensive extramedullary hematopoiesis. In
PB-MNC, a high percentage (15%) of CD42CD82TCRab1 T
cells was observed. Hypergammaglobulinemia (IgG, 13.8 g/L;
IgM, 0.85 g/L; IgA, 2.48 g/L) remained persistent for several
years. At the age of 8 mo, she had massive generalized
adenopathy of the cervical, mesenterial, and para-aortal lymph
nodes and chronic pulmonary disease not responding to bron-
chodilation and not associated with detection of pathogens.
Flow cytometric immunophenotyping of PB-MNC and
lymph node biopsy specimens indicated that 30% and 70% of
cells, respectively, were CD42CD82TCRab1 T cells. Figure
1A shows the T lymphoblast infiltration in the lymph node.
Lymphoproliferative responses to the mitogens PHA, ConA,
PWM, ProtA, and SAC, and the CD3 (OKT3) antibody indi-
cated no functional T and B cell impairment. Analysis of a
lymph node biopsy was suggestive of a T cell non-Hodgkin’s
lymphoma, but TCRB analysis did not show monoclonal or
oligoclonal rearrangements. Skin biopsy specimens taken dur-
ing relapse showed IgM and complement depositions in the
dermis consistent with lupus-like disease. At the same time,
rheumatoid factors (IgM and IgA) as well as autoantibodies
against nuclear antigens, smooth muscle, striated muscle, and
neutrophil cytoplasmic antigens were demonstrated in serum.
Subsequently, the girl remained in a stable condition without
hemolytic anemia, and her pulmonary function improved grad-
ually. At the age of 4–5 y, she had maculopapular to nodular
skin abnormalities on the face and on both arms and legs.
Clinically this skin disease resembled mycosis fungoides. Skin
biopsies showed the histopathologic aspects of malignant cu-
taneous T cell lymphoma (Fig. 1B). Approximately 30% of T
cells in the dermal infiltrates were CD31CD41CD82. DNA
analysis showed biallelic TCRB gene rearrangements in one of
the biopsy specimens, but not in others, making mycosis
fungoides less likely. A bone marrow biopsy did not reveal
abnormal T cells. Immunophenotyping of PB-MNC yielded
normal results. The girl was diagnosed with ALPS and during
the following years she became increasingly ill. Her lung
disease required continuous oxygen administration. The pare-
sis of the right arm and diaphragm persisted, whereas the
cutaneous symptoms had a chronically intermittent course. She
finally died at the age of 8 y as a result of pulmonary failure.
Blood samples and DNA and RNA extraction. PB samples
from the patient, her parents, and three healthy siblings, as well
as from healthy control subjects were obtained. MNC were
isolated from PB by Ficoll density centrifugation (Ficoll-
Paque; density, 1.077 g/mL; Pharmacia, Uppsala, Sweden).
After Ficoll density centrifugation, both MNC and granulocyte
fractions were used for DNA extraction with the phenol-
chloroform method and for RNA extraction using the method
according to Chomczynski and Sacchi (25).
Immunophenotyping. Double and triple flow cytometric
immunophenotyping was performed to study Fas (CD95) ex-
pression on granulocytes, monocytes, and CD41CD31,
CD81CD31, CD45RO1CD31, and CD45RA1CD31 T lym-
phocyte subpopulations. For this purpose, 50 mL of whole
blood or MNC was incubated with 50 mL of various combi-
nations of FITC, phycoerythrin, and phycoerythrin-cyanin-5
conjugated with CD95 (UB-2 and CH11; Immunotech, Mar-
seille, France), CD95 (DX-2; PharMingen, San Diego, CA),
Figure 1. Histomorphology of the skin and lymph node biopsies, showing the
lymphoproliferations. A, Lymph node showing infiltration with T lymphoblasts
(arrow) (hematoxylin and eosin, 31000). B, Infiltration of the skin with T
lymphoblastic lymphoma (hematoxylin and eosin, 3200).
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CD95 (7C11; Beckman Coulter, Fullerton, CA), CD3 (HIT3a),
CD4 (Leu-3a), CD8 (Leu-2a), CD45RO (UCHL1; Becton
Dickinson, San Jose, CA), and CD45RA (2H4; Coulter Clone,
Hialeah, FL) antibodies for 10 min at room temperature. After
incubation, the cells were washed, and, in the case of whole
blood, the erythrocytes were lysed with lysing solution (Becton
Dickinson). Appropriate isotype controls were performed in
every test.
To quantitate the density of Fas expression in terms of
numbers of molecules of equivalent soluble fluorochrome, the
fluorescence intensity was calibrated using Quantum FITC
premixed microbead standards (Flow Cytometry Standard
Corp., San Juan, PR).
To investigate Fas expression on stimulated T lymphocytes,
PB-MNC were cultured (0.5 3 106 cells/mL) in RPMI 1640
medium with Glutamax-I, supplemented with 100 U/mL pen-
icillin, 100 mg/mL streptomycin, and 10% FCS in the presence
of PHA (0.2 mg/mL). The cells were maintained for 7 d at 37°C
in a humidified atmosphere of 5% CO2 in air. Fas expression
was evaluated daily with triple immunostainings as described
above.
RT-PCR and RQ-PCR. cDNA was prepared from mRNA
using AMV reverse transcriptase (Promega, Madison, WI).
RT-PCR was performed with different combinations of the
cDNA primers EU, ED, CU and CD (see Fig. 4) to amplify
parts of the coding region (EU: CTGGGAATTCCTACCTCT-
GGTTCTTACGTCTG, ED: CATGAATTCATCAAGGAAT-
GCACACTCACC, CU: TGAGAAGCTTGGTTTTCCTT-
TCTGTG, CD: CTAGACCAAGCTTGGATTTCATTTC).
RT-PCR conditions were 1 min at 94°C, 1 min at 60°C, and 2
min at 72°C for 35 cycles. The PCR products were separated
on a 6% polyacrylamide gel.
For the quantification of FAS mRNA, we performed RQ-
PCR with ABI Prism 7700 Sequence Detection (PE Biosys-
tems, Foster City, CA) (26). Two FAS primers and a TaqMan
probe were designed with the ABI Prism Primer Express (PE
Biosystems) (FASTM59: TCCTCAAGGACATTACTAGT-
GACTCAG, FASTM39: ATCTTTTCAAACACTAATTG-
CATATACTCAG, FAS TaqMan probe labeled with FAM
reporter dye: GAAATCCAAAGCTTGGTCTAGAGT-
GAAAAACAAC). During the PCR the TaqMan probe first
hybridizes to the DNA target, followed by primer annealing.
The emission of the reporter dye of the TaqMan probe is
quenched until the probe is cleaved by the exonuclease activity
of the Taq polymerase, generating a fluorescent reporter signal.
The RQ-PCR conditions were 2 min at 50°C for the Am-
pErase Uracil N-glycosylase step, 10 min at 95°C to activate
AmpliTaq Gold, followed by 50 cycles of 15 s at 95°C and 1
min at 60°C. TaqMan GAPDH control reagents (PE Biosys-
tems) were used to quantify the amount of cDNA in the
reaction.
PCR of genomic DNA and heteroduplex analysis. For
amplification of genomic DNA, nine primer sets were designed
to amplify each of the nine exons. All primers were positioned
in the introns, at least 25 base pairs upstream or downstream of
the splice sites of the involved exons. The conditions for PCR
analysis of genomic DNA were essentially the same as for the
RT-PCR method. PCR products were further analyzed by
heteroduplex analysis to detect potential differences between
the exons of the two alleles. After denaturation (5 min at 94°C)
and renaturation (1 h at 4°C), the resulting duplexes (hetero-
and/or homoduplexes) were separated in nondenaturing 6%
polyacrylamide gels (27).
Southern blot analysis. Genomic DNA samples of 20 mg
were digested with EcoRI, BamHI, HindIII, or SacI. The
restriction fragments were separated in 0.7% agarose gels,
transferred to Nytran-13N nylon membranes (Scheichler and
Schuell, Dassel, Germany), and hybridized with exon 1, exon
3, and exon 9 probes (28). The probes were generated by PCR
amplification of the exons using MNC DNA from a healthy
individual and radioactively labeled with [a-32P]dATP and
[a-32P]dCTP using the random primer labeling method.
Sequence analysis. The products of both RT-PCR and
genomic PCR amplification were sequenced with the T7 Se-
quence Kit (Pharmacia) using 35S radiolabeling after cloning in
pMosBlue (Amersham Int., Amersham, UK), and the frag-
ments were run in a denaturing 8% polyacrylamide sequence
gel. Exons were also analyzed by cycle sequencing on the ABI
373 fluorescent sequencer (PE Biosystems).
RESULTS
Fas protein expression. In contrast to healthy children and
adults, the granulocytes, monocytes, and CD45RO1 T lym-
phocytes of the patient did not express detectable levels of Fas
protein (Fig. 2A). The absence of Fas expression on MNC of
the patient was confirmed with three different CD95 antibodies
(data not shown). Two family members showed intermediate
Fas protein expression (Fig. 2B), but they did not show any of
the clinical features. Furthermore, PB-MNC were stimulated in
vitro with PHA to induce Fas protein expression on activated
and proliferating T lymphocytes. As expected, within 2 d of
culture, virtually all MNC of healthy control subjects ex-
pressed Fas (Fig. 3A). Maximum levels of Fas density per cell
were reached after 4 to 5 d of culture (Fig. 3B). In contrast,
only a small fraction of the patient’s MNC (10–20%) ex-
pressed Fas at low density levels, which were 5 to 6-fold lower
than in healthy control subjects (Fig. 3).
RT-PCR analysis of FAS mRNA. The observation that FAS
RT-PCR products could be generated with the four primers
EU, ED, CU, and CD (Fig. 4A) indicated that FAS mRNA was
expressed in leukocytes from the patient. cDNA amplification
with the ED and CD primers, which are located in the extra-
cellular and cytoplasmic regions, respectively, should generate
two products: one including and one excluding the transmem-
brane region (Fig. 4A). Both in the healthy control subjects and
in the patient, two PCR products were obtained, indicating that
both splice variants were present. However, the two products
of the patient were found to be larger compared with those of
healthy control subjects (Fig. 4B). This suggested that there
may be a defect in the cytoplasmic region.
Quantification of FAS mRNA by RQ-PCR. RQ-PCR was
subsequently performed to determine whether the amount of
FAS mRNA in MNC of the patient was comparable to that of
healthy control subjects. In RQ-PCR, the CT is a measure of
the amount of template present in the sample. A GAPDH
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housekeeping gene control reaction was performed to check for
the amount of cDNA in the reaction mixture, which was found
to be equal (similar CT values) in the patient and the two
healthy control subjects (Fig. 5A). Figure 5B shows that the
amount of FAS mRNA in the patient equals the amount present
in the healthy control subjects, as evidenced from the similar
CT values.
Heteroduplex PCR analysis and sequencing of FAS exons.
All FAS exons were amplified using intron primers, and the
resulting PCR products were subjected to heteroduplex analy-
sis to find possible allelic differences. Heteroduplex analysis is
based on denaturation and renaturation of the PCR products,
leading to the formation of one homoduplex in a homozygous
situation and two homoduplexes as well as two heteroduplexes
in a heterozygous situation. Homo- and heteroduplexes can be
separated by PAGE on the basis of the differences in confor-
mation. Heteroduplexes are more retarded in a polyacrylamide
gel because of mismatches or bulging loops. At low renatur-
ation temperatures (,20°C) some single-strand PCR products
will remain that have a different (generally lower) mobility
compared with heteroduplexes in gel electrophoresis. Using
this assay for PCR products derived from exons 1 to 8, only
homoduplexes and no heteroduplexes were found in the pa-
tient, her family members, and healthy control subjects. More-
over, in these exons, no size differences were found between
patient, siblings, and control subjects (data not shown). How-
ever, the homoduplexes of the PCR products of exon 9 of the
patient and control subjects showed a difference in size similar
to that seen with the ED and CD primers in the RT-PCR
analysis (Fig. 6, A and B), suggesting that the patient was
homozygous for a larger exon 9 product. Hemizygosity of the
FAS gene in the patient was excluded, because Southern blot
analysis showed equal band intensities in the patient and
control subjects, suggesting the presence of two FAS alleles
without major deletions or rearrangements (data not shown). In
the family members, we identified two homoduplexes, repre-
senting the allele with the normal and the one with the larger
exon 9 product, as well as two heteroduplexes, representing
cross-annealed single-strand fragments of the two alleles (Fig.
6B). These findings were further supported by the presence of
two single-strand bands in the lanes of samples from the patient
and control subject, which represent the coding and noncoding
fragments of the homozygous alleles. In the lanes of samples
Figure 2. Fas (CD95) expression on freshly obtained blood leukocytes of the
patient and a healthy control subject. A, Dot plots show CD95 (UB-2)
expression vs side scatter (SSC) of the leukocytes. In the healthy control
subject, Fas expression is found on granulocytes, monocytes, and a part of the
lymphocytes. Detailed immunophenotyping revealed that natural killer cells
and B lymphocytes do not express detectable levels of Fas, whereas CD45RO1
T lymphocytes are Fas-positive. This is in contrast to the patient, who did not
show detectable Fas levels on any leukocyte subset. B, Fas expression on
CD31 T lymphocytes of healthy control subjects, family members, and the
patient. Healthy control subjects show strong positivity on a subset of the T
lymphocytes, whereas other T cells are weakly positive. The T lymphocytes of
the parents show intermediate Fas expression, whereas the majority of the T
lymphocytes in the siblings are weakly Fas-positive, with comparable intensity
as a T cell subset in healthy control subjects. The patient’s T lymphocytes are
negative for Fas expression. The low number of events in the patient is caused
by lymphopenia.
Figure 3. Fas (CD95) expression on cultured MNC from the patient and
healthy control subjects. A, PHA-stimulated MNC cultures of healthy age-
matched and adult control subjects resulted in Fas expression on virtually all
MNC within 2 d. These MNC mainly consisted of CD45RO1CD31 T lym-
phocytes, as was the case in the patient’s culture. However, only a minor
fraction of the patient’s cells expressed Fas. B, The density of the Fas
expression (number of molecules of equivalent soluble fluorochrome, MESF
values) in the patient was essentially lower than in the healthy control subjects.
339HOMOZYGOUS FAS DEFECT IN A CHILD WITH ALPS
from the family members, three single-stranded bands were
observed, representing the coding and noncoding fragments of
the two different alleles, two of which probably comigrated
(Fig. 6B).
Sequencing of FAS exon 9 revealed a duplication of 20
nucleotides (Fig. 6C). In the cDNA, the same mutation was
found. This duplication causes a frameshift resulting in an
extended predicted protein (Fig. 6D). The six C-terminal amino
acids (Glu-Ile-Gln-Ser-Leu-Val) are replaced by 37 amino
acids. The second and third amino acids in the altered reading
frame are not changed as a result of the duplication. Sequenc-
ing of all other exons revealed no additional mutations.
DISCUSSION
The patient reported here developed the classic features of
ALPS immediately after birth. She showed all phenotypic
characteristics, including cutaneous lupus-like disease at a later
stage. Moreover, the patient showed histologically malignant
lymph nodes, although monoclonal or oligoclonal rearrange-
ments could not be detected on TCRB gene analysis. Both the
early onset and the extensiveness of the ALPS characteristics
suggest that the phenotype of the reported patient was very
severe compared with other patients with ALPS that have
previously been described (Table 1). The consanguineous par-
ents and siblings of the patient did not show these autoimmune
features and lymphoproliferations.
Immunophenotyping demonstrated that leukocytes of the
patient did not show detectable levels of Fas protein, whereas
the expression on leukocytes of the family members was
intermediate. In vitro stimulation of PB-MNC resulted in low
levels of Fas expression on only a minor fraction of the
proliferating T cells. This suggests that Fas protein can poten-
tially be expressed, but only with strong stimuli in vitro.
Molecular analysis was performed to determine the genotype
of the patient. RT-PCR data showed that both the FAS and
FASDTM splice variants were present, although they were
enlarged in the region encoding the cytoplasmic part of the
protein. Quantitative mRNA analysis with RQ-PCR showed
that the same amount of FAS mRNA was present in the patient
compared with the healthy control subjects. This made a
transcriptional defect unlikely. Heteroduplex PCR analysis of
the FAS gene exons and sequencing analysis showed that the
patient had a homozygous duplication of 20 bp in the death
domain encoding exon 9. The patient is most probably not
hemizygous for this mutation, because Southern blot analysis
of the patient did not show any abnormality compared with
healthy control subjects and family members. The duplication
introduces a frameshift resulting in a longer predicted protein,
which might be less stable or defective in proper transport to
the cell surface. Both parents and siblings were heterozygous
for this mutation and did not show typical ALPS features.
Therefore, this patient carries a unique homozygous recessive
mutation in the FAS gene.
All previously described patients with ALPS are phenotyp-
ically largely comparable as is shown in Table 1. However,
Figure 4. RT-PCR analysis of FAS mRNA. A, Schematic diagram of FAS
mRNA encoding the extracellular, transmembrane (TM), and cytoplasmic
domain. Four primers for RT-PCR are indicated as well as the size of the two
ED-CD RT-PCR products, including and excluding the transmembrane do-
main. B, PAGE analysis of the ED-CD RT-PCR products of the patient and a
healthy control subject. The two products of the patient are larger in compar-
ison to those of the healthy control subject.
Figure 5. RQ-PCR analysis of FAS mRNA. A, Control GAPDH cDNA
amplification plot of GAPDH RQ-PCR of cDNA of patient and healthy control
subjects. B, FAS cDNA amplification plot of patient and healthy control
subjects showing equal levels of FAS expression.
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considerable differences are found in severity, age of onset, and
in the presence or absence of some specific characteristics. All
patients showed lymphoproliferations, but the manifestation of
the autoimmune features varied. Even siblings or other family
members carrying the same mutation (patients 1a and b, pa-
tients 10 a, b, and c, and patients 13 a, b, and c) showed
differences in the extent of autoimmune features (19, 21, 23).
In lpr and lprcg mice, FAS mutations result in lymphoprolif-
erations, whereas autoimmunity in these mice is strongly in-
fluenced by the genetic background (29). The collective patient
data suggest that also in man genetic background might influ-
ence the clinical manifestation of autoimmune features.
On the basis of different genotypes, three groups of patients
with ALPS can be distinguished. The first group includes
patients with a heterozygous FAS mutation (patients 1–10 in
Table 1), suggesting a dominant-negative defect in Fas-
mediated apoptosis. Healthy family members of these patients
with ALPS who have a heterozygous FAS mutation showed
defects in in vitro Fas-mediated apoptosis without clearly
showing the clinical symptoms, although some of the family
members of patients 3, 4, 6, and 10 in Table 1 did show a few
ALPS symptoms. In case a particular mutation does not cause
clinical symptoms in the family members, it might well be that
the involved FAS mutation is not the single cause of ALPS in
these children. It is likely that another defect, for example
affecting FasL or downstream signaling molecules of Fas-
mediated apoptosis, is inherited from the parent without the
FAS gene defect. Candidates for Fas-mediated signaling de-
fects are proteins that associate with the death domain, such as
RIP, FADD, and FLICE (30–33). One could speculate that in
this situation, ALPS may result from a digenic defect. In that
case the FAS mutation might be called autosomal recessive,
although this can formally only be proven in a clinically
symptomatic individual showing the homozygous FAS muta-
tion. It remains unclear whether another defect is also present
in heterozygous family members showing only a few clinical
symptoms of ALPS. So far, symptomatic heterozygous Fas-
deficient mice have not been described.
A second group of patients with ALPS (patients 11-13 in
Table 1) is associated with biallelic recessive mutations. In
these patients, both alleles are affected, whereas heterozygous
family members do not show clinical symptoms. Our patient
reported here (patient 11) carries the same mutation on both
alleles and is therefore homozygous for this recessive FAS
gene mutation. Recessive mutations are also found in the lpr,
lprcg, and Fas-null mice. Lpr mice having a transposon in
intron 2 are able to express low levels of normal FAS mRNA,
implying that they are not completely deficient for Fas. Lprcg
mice express Fas protein on the membrane, although this
protein is not functional because of one amino acid substitu-
tion. Fas-null mice are completely Fas protein deficient and
display the same phenotype as lpr mice, but the phenotype is
more severe and accelerated in presentation. Fas-null mice also
have liver cell hyperplasia, which is not seen in lpr and lprcg
mice (5). Therefore, it is clear that the type of FAS gene
mutation determines the level of (aberrant) protein expression
and thereby influences the severity of the phenotype. The
patient studied in this report (patient 11) carries a homozygous
mutation affecting the cytoplasmic tail of the protein. This
mutation severely affects Fas protein expression. Patient 12
also lacks Fas expression because of a homozygous deletion of
the last 290 bp. Both patients had ALPS from birth on and
showed all characteristic ALPS symptoms. It is therefore
tempting to compare these human FAS gene mutations with the
murine Fas-null mutation, in which deletion of the death
domain also affects Fas protein expression. However, the hep-
atomegaly in our patient was not clearly caused by liver cell
hyperplasia, but was probably caused by erythropoiesis and
some swelling of the hepatocytes. There was no striking dif-
ference in nuclear sizes in comparison with an age-matched
liver from a girl who died of sudden infant death syndrome.
The patients described by Bettinardi et al. (21) (patients
13 a, b, and c) also have double mutations, but these concern
different missense point mutations on the two alleles. These
mutations do not seem to disturb trimerization, but result in the
expression of a Fas trimer on the membrane, which is appar-
ently not entirely functional. The slightly reduced Fas expres-
sion in these patients was explained by reduced density rather
than by a conformational change. On the basis of severity, age
of onset, and type of mutation, these patients are phenotypi-
cally and genotypically similar to lprcg mice.
Figure 6. PCR and sequence analysis of the FAS gene. A, Schematic repre-
sentation of the entire FAS gene. The enlarged exon 9 consists of a coding
region (shaded) and 39 untranslated region (UTR) (blank). Primers 9U and 9D
were used for amplification and subsequent analysis of exon 9. B, Heterodu-
plex analysis of exon 9 PCR products of the patient, her family members, and
five healthy control subjects. The control subjects and the patient (last lane) are
homozygous for exon 9 as evidenced from the presence of one homoduplex
and two single-strand bands. The homoduplex of the patient is larger than the
homoduplex of the control subjects. The presence of two homoduplexes and
two heteroduplexes shows that the family members are heterozygous for exon
9. C, Sequence analysis of exon 9 using the 9D primer. The duplication of 20
base pairs in the patient is indicated. D, Predicted amino acid sequence of the
C-terminus of the patient’s Fas protein in comparison to the wild-type Fas
protein sequence.
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In addition, yet a third group of patients with ALPS has been
reported by Sneller et al. (22) and Dianzani et al. (34). These
patients show the same clinical features, but do not carry a FAS
gene mutation. Probably, a defect in FasL or in the signaling
pathway downstream of Fas, gives rise to deficient Fas-
mediated apoptosis.
In summary, ALPS is caused by defective Fas-mediated
apoptosis related to a monoallelic defect in the FAS gene,
possibly accompanied by an additional defect and thereby
potentially recessive, although there are some examples in
which dominant inheritance of the FAS gene cannot be ex-
cluded. A biallelic defect in the FAS gene is another possibility
for ALPS. The mutation found in the patient studied here
clearly demonstrated recessive inheritance of ALPS. The syn-
drome can also be found in patients lacking a FAS mutation.
The severity of the syndrome as determined by the presence of
the typical ALPS characteristics and the age of onset is depen-
dent on the type of mutation. Decreased levels of trimer Fas
expression seem to result in milder ALPS forms, whereas
complete absence of the Fas protein as observed in our patient
induces the severe ALPS phenotype.
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